Refsum disease (Refsum erythroderma) in infants is a rare genetic disorder characterized by a disorder of fatty acid metabolism. This inherited disorder results from a deficiency of the enzyme alpha-oxidase, which is responsible for breaking down phytanic acid, a complex substance found in certain foods and animal fats. The accumulation of phytanic acid in the body can lead to numerous disorders, including skin changes, neurological symptoms, and systemic pathologies. Symptoms can appear in early childhood, but diagnosis is often delayed because the clinical picture is ambiguous and the condition is difficult to recognize in the early stages.
History of the disease and interesting historical facts
The name "Refsum disease" comes from the Swedish dermatologist who first described the condition in 1929. However, wider publication and research of the disease began later, in 1966, when doctors identified a link between alpha-oxidase deficiency and the symptoms of the disease. It was later established that the condition is hereditary. In most cases, Refsum disease is observed in people of Northern European descent, indicating a geographic and ethnic predisposition. During the study of the disease, scientists have discovered many interesting facts, including a close relationship between careful study of diet and the development of the disease, which opened up new horizons in approaches to its treatment.
Epidemiology
The prevalence of Refsum disease, according to modern studies, is approximately 1 in 1,000,000 newborns. Despite its rarity, there is an increased likelihood of developing the disease in people with a family history of this condition. Variants of the disease may include their own variations in manifestations and progression, which creates certain difficulties in diagnosing and recording statistical data. Almost all cases were registered in countries with a high standard of living, where genetic analysis is available, allowing for the detection of diseases at earlier stages, thereby simplifying their diagnosis and treatment.
Genetic predisposition to this disease
Refsum disease is an autosomal recessive disorder because it is associated with mutations in the PHYH (phytanic acid α-oxidase) gene. The most common mutations that cause the disease involve regions of this gene, resulting in the absence or deficiency of the enzyme responsible for metabolizing phytanic acid. Typically, both parental lines must be carriers of the mutation for a child to develop the disease. Genetic studies show that more than 90% cases of Refsum disease are associated with one of the known mutations in this gene, confirming the dominant role of genetic predisposition.
Risk factors for the development of this disease
Risk factors for Refsum disease focus on heredity, but a number of exogenous factors can also be identified that contribute to the development of various symptoms. The main risk factors include:
- Having relatives with a history of Refsum disease.
- Problems with fatty acid metabolism in parents.
- An unhealthy diet containing high levels of phytanic acid may worsen symptoms.
- Climatic conditions in which ailments may develop, however, these factors are not direct triggers of the disease.
Diagnosis of this disease
Diagnosis of Refsum disease is based on a combination of clinical symptoms and laboratory tests. The main symptoms include:
- Scleroderma-like changes on the skin.
- Progressive neuropathy.
- Cataract.
- Problems with the cardiovascular system.
Laboratory tests include blood tests to check for phytanic acid levels, as well as genetic testing to look for mutations in specific genes. Radiological examinations may reveal changes in the skeletal system or other organs, while other diagnostics involve assessing visually observed symptoms. Differential diagnosis should include diseases such as Turner syndrome, spinal muscular atrophy, and other conditions that have similar symptoms.
Treatment
Treatment of Refsum disease is aimed at reducing the level of phytanic acid and relieving symptomatic manifestations. The most effective approaches to treatment are:
- Dietary therapy: Limit foods high in phytanic acid, including meat, dairy products, and fish.
- Pharmacological treatment: drugs that reduce phytanic acid levels and increase metabolic activity.
- Surgical treatment: in cases where serious complications arise, such as cataracts.
- Physiotherapy and rehabilitation: to improve quality of life and full participation in life processes.
List of medications used to treat this disease
The following drugs are currently used to treat Refsum disease:
- Niacin (vitamin B3) - helps reduce phytanic acid levels.
- Medicines for metabolic correction.
- Taking in the included polyunsaturated fatty acids to maintain the health of cell membranes.
Disease monitoring
Monitoring of the patient's condition with Refsum disease is organized through regular revisions of clinical manifestations and laboratory parameters. Monitoring stages include:
- Periodic assessment of blood phytanic acid levels.
- Check for complications (eg, cataracts) every 6-12 months.
- Monitoring the condition of the skin and nervous system.
The prognosis for patients depends on the timeliness and quality of treatment. However, without proper monitoring and treatment, the risk of developing serious problems such as cardiovascular diseases and nervous disorders increases significantly.
Age-related features of the disease
In infancy, the disease may manifest itself in the form of dermatological manifestations and neurological symptoms, but in children over 2-6 years of age, the clinical picture may become significantly more complicated against the background of progression of processes in the body, which requires a more serious approach to diagnosis and treatment. In adults, the symptoms become more pronounced and may include serious disturbances in the functioning of the cardiovascular and nervous systems.
Questions and Answers
- What are the symptoms of Refsum disease? The main symptoms include skin changes, neurological disorders and cardiovascular problems.
- How is Refsum disease diagnosed? Diagnosis is based on clinical manifestations, phytanic acid level analysis and genetic testing.
- What are the risk factors associated with the disease? Family history, poor nutrition and genetic mutations.
- What is the treatment for Refsum disease? Treatment includes dietary therapy, pharmacological treatment and physical therapy.
- What is the prognosis for children with Refsum disease? The prognosis depends on the severity of symptoms and the effectiveness of treatment, the youth group has an increased risk of complications without control.
Dr. Oleg Korzhikov recommends paying attention to the timely detection of symptoms of Refsum disease, as well as regular examinations by geneticists to analyze the presence of mutations. Parents should be aware of nutritional rules, avoiding products that may contain phytanic acid to minimize symptoms. In addition, support from rehabilitation professionals can play an important role in improving the quality of life of children with this disease.
